Alpha 2.0
Login Register
» Authors » Gaobo Chai

Gaobo Chai

Explore the profile of Gaobo Chai including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 53
Followers 0
Related Specialties
Pharmacology
Biochemistry
Chemistry
Top 10 Co-Authors
Ting Song
Zhichao Zhang
Xiaoyan Yu
Xiangqian Li
Ziqian Wang
Yubo Liu
Pengchen Su
Yingang Feng
Yudan Fan
Keren Zhang
Published In
Chembiochem
Br J Pharmacol
Eur J Pharm Sci
Angew Chem Int Ed Engl
Arch Pharm (Weinheim)
Affiliations
Soon will be listed here.
Recent Articles
1.
Systems analysis of phosphorylation-regulated Bcl-2 interactions establishes a model to reconcile the controversy over the significance of Bcl-2 phosphorylation
Song T, Wang P, Yu X, Wang A, Chai G, Fan Y, et al.
Br J Pharmacol . 2018 Dec; 176(3):491-504. PMID: 30500985
Background And Purpose: The biological significance of the multi-site phosphorylation of Bcl-2 at its loop region (T69, S70 and S87) has remained controversial for decades. This is a major obstacle...
2.
Deactivation of Mcl-1 by Dual-Function Small-Molecule Inhibitors Targeting the Bcl-2 Homology 3 Domain and Facilitating Mcl-1 Ubiquitination
Song T, Wang Z, Ji F, Feng Y, Fan Y, Chai G, et al.
Angew Chem Int Ed Engl . 2016 Oct; 55(46):14250-14256. PMID: 27701804
By means of limited proteolysis assay, three-dimensional NMR, X-ray crystallography and alanine mutations, a dynamic region at the Q221R222N223 motif in the Bcl-2 homology 3 (BH3) domain of Mcl-1 has...
3.
Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding
Song T, Chai G, Liu Y, Yu X, Wang Z, Zhang Z
Br J Pharmacol . 2015 Oct; 173(3):471-83. PMID: 26493374
Background And Purpose: Although the ongoing clinical trials of ABT-263 and ABT-199 in chronic lymphocytic leukaemia (CLL) have indicated that BH3 mimetics hold considerable promise, understanding the mechanism of CLL...
4.
Discovery of a small-molecule pBcl-2 inhibitor that overcomes pBcl-2-mediated resistance to apoptosis
Song T, Yu X, Liu Y, Li X, Chai G, Zhang Z
Chembiochem . 2015 Feb; 16(5):757-65. PMID: 25711460
Although the role of Bcl-2 phosphorylation is still under debate, it has been identified in a resistance mechanism to BH3 mimetics, for example ABT-737 and S1. We identified an S1...
5.
Novel Mcl-1/Bcl-2 dual inhibitors created by the structure-based hybridization of drug-divided building blocks and a fragment deconstructed from a known two-face BH3 mimetic
Zhang Z, Su P, Li X, Song T, Chai G, Yu X, et al.
Arch Pharm (Weinheim) . 2015 Feb; 348(2):89-99. PMID: 25641608
We have previously reported a small-molecule two-face Bim BH3 mimetic, 2,3-dihydroxy-6-(4-isopropylphenylthio)anthracene-9,10-dione (1). Herein, we linked a polyphenol fragment, which was deconstructed from compound 1, with a drug-derived building block gained...
6.
Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition
Song T, Chai G, Liu Y, Xie M, Chen Q, Yu X, et al.
Eur J Pharm Sci . 2015 Jan; 70:64-71. PMID: 25596561
Paclitaxel is an alternative chemotherapeutic agent for chronic myelogenous leukemia (CML) when primary or secondary resistance of tyrosine kinase inhibitors (TKI) is emerging, because paclitaxel could bypass the apoptotic deficiencies...
7.
Two-face, two-turn α-helix mimetics based on a cross-acridine scaffold: analogues of the Bim BH3 domain
Li X, Wang Z, Feng Y, Song T, Su P, Chen C, et al.
Chembiochem . 2014 May; 15(9):1280-5. PMID: 24838655
The design of a cross-acridine scaffold mimicking the i, i+3, i+5, and i+7 residues distributed over a two-face, two-turn α-helix is described. Docking studies and 2D (1)H, (15)N HSQC NMR...